aTyr Pharma, Inc. (ATYR)
Automate Your Wheel Strategy on ATYR
With Tiblio's Option Bot, you can configure your own wheel strategy including ATYR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATYR
- Rev/Share 0.0
- Book/Share 0.8656
- PB 5.9923
- Debt/Equity 0.1731
- CurrentRatio 7.7947
- ROIC -0.7632
- MktCap 462822880.0
- FreeCF/Share -0.7193
- PFCF -7.44
- PE -7.0921
- Debt/Assets 0.1336
- DivYield 0
- ROE -0.8687
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ATYR | Leerink Partners | -- | Outperform | -- | $16 | Feb. 18, 2025 |
| Initiation | ATYR | Cantor Fitzgerald | -- | Overweight | -- | -- | Jan. 6, 2025 |
| Initiation | ATYR | Wells Fargo | -- | Overweight | -- | $17 | Oct. 4, 2024 |
| Initiation | ATYR | Jefferies | -- | Buy | -- | $9 | Sept. 5, 2024 |
News
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence shows target market for efzofitimod in pulmonary sarcoidosis is higher than previously estimated with increased morbidity.
Read More
aTyr Pharma to Participate in April Investor Conferences
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2025. Details of the conferences appear below: Conference: Jones Healthcare and Technology Innovation Conference Date: April 8 – 9, 2025Location: Las Vegas, NVFormat: 1x1 Investor Meetings Conference: Piper Sandler Spring Biopharma Symposium Date: April 17, 2025Location: Boston, MAFormat: 1x1 Investor Meetings For more information on how to register, please …
Read More
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise.
Read More
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year?
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Atyr Pharma (ATYR) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
Read More
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D.
Read More
About aTyr Pharma, Inc. (ATYR)
- IPO Date
- Website https://www.atyrpharma.com
- Industry Biotechnology
- CEO Dr. Sanjay S. Shukla M.D., M.S.
- Employees 56